Delivery Order SPE2DB24D3013-SPE2DB25FFQTB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ibrance 100 mg tablets (7-count packages) with a ceiling value of $8,122.48. This is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was competitively awarded with no set-aside designation. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, supporting the federal government's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibrance 75 mg tablets in a quantity of seven units, with a ceiling value of $32,495.84. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for ultimate completion on October 8, 2025, with performance taking place at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $8,123.96 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Ibrance 75 mg tablets (7-count packaging). This is a non-set-aside competitive award with performance completion scheduled for October 3, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ibrance 125 mg tablets in a quantity of seven units, with a ceiling value of $8,118.08. This firm fixed-price delivery order, which is expected to be completed by September 10, 2025, carries no set-aside designation and represents a competitively awarded transaction. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg tablets (7-count packaging) on September 9, 2025, with a completion date of September 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside arrangement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-count), valued at $8,122.48 under a firm fixed price contract. This non-set-aside delivery order is scheduled for completion by September 3, 2025, with performance of work occurring at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ibrance 100 mg tablets (7-count packaging) with a ceiling value of $8,122.48. This firm fixed-price delivery order, with an ultimate completion date of October 9, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and fulfillment will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ibrance 75 mg capsules (21-count units) under a firm fixed-price contract. The order carries a ceiling value of $16,247.92 and is scheduled for completion by September 12, 2025. This is a non-set-aside competitive award executed from AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.999 billion global...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQTBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Ibrance 75 mg tablets in packages of seven units, with a ceiling value of $8,123.96 and firm fixed pricing. This is a non-set-aside, competitively awarded contract with an ultimate completion date of October 10, 2025, and performance to be fulfilled at the vendor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor for medical procurement, particularly supporting the Defense Health Agency and military healthcare systems. The broader SPE2DX IDC encompasses a wide range of pharmaceutical products and medical supplies including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. This delivery order for Ibrance, an oncology medication, exemplifies the company's role in supplying specialized pharmaceutical products to federal healthcare systems through the DLA's established procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/19/25 |